A Study of DU-176b in Preventing Blood Clots After Hip Replacement Surgery

Summary

This study is to assess if DU176b is effective in prevention of blood clots following hip replacement surgery. The duration is 7-10 days of treatment and 30 and 60 day follow-up visits.

Timeline

Start

2006-05

Primary completion

2007-06

Completion

2007-06

Outcome

Met primary endpoint

registry Edoxaban 15mg QD vs Dalteparin; p = 0.003; Fisher Exact NCT00398216 ↗

registry Edoxaban 30mg QD vs Dalteparin; p <0.001; Fisher Exact NCT00398216 ↗

registry Edoxaban 60mg QD vs Dalteparin; p <0.001; Fisher Exact NCT00398216 ↗

registry Edoxaban 90mg QD vs Dalteparin; p <0.001; Fisher Exact NCT00398216 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Edoxaban	Small molecule	—	—

Indications